End-of-day quote
Korea S.E.
06:00:00 2024-04-29 pm EDT
|
5-day change
|
1st Jan Change
|
68,200
KRW
|
+3.33%
|
|
+9.47%
|
-2.85%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
---|
Capitalization
1 |
711,430
|
432,892
|
555,758
|
Enterprise Value (EV)
1 |
639,272
|
380,215
|
491,213
|
P/E ratio
|
-30
x
|
-23.7
x
|
-13.1
x
|
Yield
|
-
|
-
|
-
|
Capitalization / Revenue
|
445
x
|
582
x
|
504
x
|
EV / Revenue
|
400
x
|
511
x
|
445
x
|
EV / EBITDA
|
-32.2
x
|
-20.8
x
|
-31.6
x
|
EV / FCF
|
-
|
-31,615,492
x
|
-33,495,286
x
|
FCF Yield
|
-
|
-0%
|
-0%
|
Price to Book
|
8.4
x
|
6.14
x
|
18.5
x
|
Nbr of stocks (in thousands)
|
7,852
|
7,885
|
7,917
|
Reference price
2 |
90,600
|
54,900
|
70,200
|
Announcement Date
|
3/23/23
|
3/23/23
|
3/21/24
|
Fiscal Period: December |
2021
|
2022
|
2023
|
---|
Net sales
1 |
1,597
|
743.5
|
1,103
|
EBITDA
1 |
-19,851
|
-18,310
|
-15,548
|
EBIT
1 |
-20,725
|
-19,386
|
-17,090
|
Operating Margin
|
-1,297.54%
|
-2,607.47%
|
-1,548.84%
|
Earnings before Tax (EBT)
1 |
-20,692
|
-18,177
|
-42,340
|
Net income
1 |
-20,692
|
-18,177
|
-42,340
|
Net margin
|
-1,295.49%
|
-2,444.93%
|
-3,837.21%
|
EPS
2 |
-3,015
|
-2,314
|
-5,351
|
Free Cash Flow
|
-
|
-12,026
|
-14,665
|
FCF margin
|
-
|
-1,617.59%
|
-1,329.08%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
Announcement Date
|
3/23/23
|
3/23/23
|
3/21/24
|
Fiscal Period: December |
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
Net Cash position
1 |
72,158
|
52,677
|
64,544
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-12,026
|
-14,665
|
ROE (net income / shareholders' equity)
|
-
|
-23.4%
|
-84.2%
|
ROA (Net income/ Total Assets)
|
-
|
-14.9%
|
-12.6%
|
Assets
1 |
-
|
122,350
|
334,721
|
Book Value Per Share
2 |
10,785
|
8,937
|
3,801
|
Cash Flow per Share
2 |
1,611
|
2,050
|
4,359
|
Capex
1 |
604
|
5,362
|
6,541
|
Capex / Sales
|
37.79%
|
721.21%
|
592.84%
|
Announcement Date
|
3/23/23
|
3/23/23
|
3/21/24
|
|
1st Jan change
|
Capi.
|
---|
| -2.85% | 391M | | +26.28% | 42.68B | | -3.99% | 42.4B | | +45.32% | 40.04B | | -6.20% | 28.31B | | +6.36% | 24.94B | | -21.47% | 18.96B | | +27.58% | 12.3B | | -2.75% | 11.95B | | -2.02% | 11.55B |
Other Biotechnology & Medical Research
|